ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC. (Q40788340)

23 September 2017

ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC. (English)

1 reference

Adaptive radiation therapy

23 September 2017

0 references

1 reference

8

Dahl O

1 reference

23 September 2017

Bernier J

1

1 reference

23 September 2017

Denekamp J

2

1 reference

23 September 2017

Rojas A

3

1 reference

23 September 2017

Trovò M

4

1 reference

23 September 2017

Horiot JC

5

1 reference

23 September 2017

Hamers H

6

1 reference

23 September 2017

Antognoni P

7

1 reference

23 September 2017

Richaud P

9

1 reference

23 September 2017

Kaanders J

10

1 reference

23 September 2017

van Glabbeke M

11

1 reference

23 September 2017

Piérart M

12

1 reference

23 September 2017

1 August 1999

1 reference

Radiotherapy and Oncology

23 September 2017

1 reference

23 September 2017

52

1 reference

23 September 2017

2

1 reference

23 September 2017

149-156

1 reference

Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

ARCON--current status: summary of a workshop on preclinical and clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

A convenient and reliable method for carbogen breathing in man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with non-small cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900106-1

7 January 2021

10.1016/S0167-8140(99)00106-1

Identifiers

DOI

1 reference

23 September 2017

1 reference